Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Active ingredients: selegiline
What it is used for
May be of benefit as an adjunct in the management of late stage Parkinson's disease in patients being treated with levodopa with/without a peripheral decarboxylase inhibitor, who exhibit deterioration in the quality of their response of therapy. INDICATIONS AS AT 1 DECEMBER 1999: Treatment of patients with Parkinson's disease. It can be used as monotherapy in the early phases of the disease and as adjunctive therapy with levodopa (with/without a peripheral decarboxylase inhibitor).
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 25 degrees Celsius
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
6mm white normal convex tablet, debossed SN/5 on one side, G on the reverse.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient selegiline
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Medical options for Parkinson's | Parkinson's Australia
Parkinson's is primarily related to a lack of dopamine as a result of degeneration of dopamine producing neurons within the mid-brain.
Read more on Parkinson's Australia website
Parkinson's disease: Q and A - myDr.com.au
Parkinson's disease is a degenerative disease of the nervous system thatcauses disturbances in initiating, controlling and co-ordinating movement. The symptoms graduallyget worse over
Read more on myDr website
Monoamine oxidase B inhibitors for early Parkinson's disease | Cochrane
Parkinson's disease is a disabling condition of the brain characterized by slowness of movement, shaking, stiffness, and in the later stages, loss of balance. Many of these symptoms are due to the loss of certain nerves in the brain, which results in the lack of a chemical called dopamine. Current treatments for Parkinson's are designed to increase dopamine by using levodopa (Sinemet or Madopar), which is converted in the brain into dopamine, or drugs that mimic dopamine (dopamine agonists). Although useful, these treatments do not slow the progression of the disease and can be associated with side-effects e.g. after a while levodopa use can cause involuntary movements (dyskinesia), painful leg cramps (dystonia) and a shortened response to each dose (motor fluctuations). Monoamine oxidase B (MAO-B) inhibitors such as selegiline (Eldepryl or Selgene) boost the levels of dopamine by a different mechanism, which may reduce the risk of these complications and slow disease progression. We reviewed 11 controlled trials with a total of 2514 patients that compared giving MAO-B inhibitors with not giving them in people with early Parkinson's to see if it was safe and effective. The results show that, although MAO-B inhibitors do improve symptoms of Parkinson's and delay the need for levodopa by a few months, they are too weak to have a major effect and do not seem to delay the progression of the condition. They may, however, reduce motor fluctuations although more information is needed to be certain of this. Although they can cause some side-effects, these are generally mild.
Read more on Cochrane (Australasian Centre) website